Chris Wright

“We continue to make strong progress on our WVE-007 clinical development plan. Let's start with our Phase 2A monotherapy trial. This is a global placebo-controlled trial enrolling individuals living with obesity with BMI of 35 to 50 and comorbidities.”

“As you recently announced, we're excited to have advanced 007 to a population well-suited to its mechanism of action. We would expect even more pronounced effects on visceral and subcutaneous fat loss.”

“The second quarter demonstrated strong operational execution as our team continued to deliver proven quality services amidst commodity price volatility and heightened geopolitical uncertainty.”

“I'll begin by discussing our recent data and plans to accelerate development of WVE-007. In March, we shared interim data from the Phase I portion of our ongoing in-light clinical program.”

“Good morning, everyone, and thank you for joining us to discuss our first quarter 2026 operational and financial results. Our first quarter results were driven by outsized demand for Liberty's premium completion service offering, outstanding operational execution, and technology-driven efficiency gains.”